The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Angeles Alvarez Secord, MD

Latest:

Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian Cancer

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Angeles Alvarez Secord, MD, Duke University Medical Center

Angeles Alvarez Secord, MD, Duke University School of Medicine

Angelica D'Aiello, MD

Latest:

Early-Stage NSCLC Is Ripe for Change

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Angelica Welch

Latest:

Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Angelo Fama, MD

Latest:

Dr. Fama on GBV-C Infection and Risk of Lymphoma

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

Angus Dalgleish, MD

Latest:

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Ani Balmanoukian, MD

Latest:

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

Ani S. Balmanoukian, MD

Latest:

Dr. Balmanoukian on Clinical Trials With Immunotherapy in GU Cancers

Ani S. Balmanoukian, MD, director of Thoracic Oncology, and associate director of the Phase I Immune-Oncology Program at The Angeles Clinic and Research Institute, discusses the importance of clinical trials investigating immunotherapy for patients with genitourinary (GU) cancers.